Latest Updates

5/18/2018 - Targeted Therapies

5/7/2015 - Immunotherapy
  • Expansion of approval of VEGFR-2 inhibitor ramucirumab to include for metastatic colorectal cancer

1/28/2015 - Immunotherapy
  • Special nursing implications for patients receiving blinatumomab, the first bispecific CD19-directed CD3 T cell–engager and first single-agent immunotherapy agent approved for the treatment of patients with Philadelphia chromosome–negative relapsed or refractory B-cell precursor ALL
  • Patients with melanoma now have more treatment options as another immune checkpoint inhibitor, nivolumab, was approved for use in patients with advanced or unresectable melanoma
  • Approval of VEGFR-2 inhibitor ramucirumab has been expanded beyond gastric and gastroesophageal junction adenocarcinoma to include patients with metastatic non-small-cell lung cancer

11/7/2014 - Immunotherapy
  • New indication for ramucirumab for advanced gastric or gastro-esophageal junction adenocarcinoma

9/30/2014 - Immunotherapy
  • Expert insight on the nursing implications of the FDA approval of the first PD inhibitor, pembrolizumab, for use in patients with advanced or unresectable melanoma who are no longer responding to other drugs

6/9/2014 - Immunotherapy
  • CTLA4 immune checkpoint inhibitors, such as ipilimumab, can cause a spectrum of autoimmune-related side effects, including diarrhea

5/7/2014 - Immunotherapy
  • Providers now have a new treatment option for patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with the approval of ramucirumab

4/24/2014 - Pain

4/18/2014 - Immunotherapy
  • Ofatumumab now approved for first line therapy in patients with CLL

3/19/2014 - Constipation and Diarrhea

12/27/2013 - Immunotherapy
  • Gail Wilkes, MS, RN, RNC, ANP-BC, MS, AOCN, provides a guide to the nursing care of patients receiving the latest immunotherapy agents, which include monoclonal antibodies, the new checkpoint inhibitors, and cancer vaccines.

12/27/2013 - Treatment of Older Adults
  • Diane Cope, PhD, ARNP-BC, AOCNP®, describes clinical considerations for the management of older adults receiving cancer treatment.